Effecte of Subacromial Injection of Tranexamic Acid Combined with Ropivacaine Versus Ropivacaine Alone to Enhance pain and functional score outcome after Arthroscopic Rotator Cuff Repair Rotator Cuff Injuries, Rotator Cuff/surgery, Arthroscopy, Arthroscopic Surgical Procedures, Tranexamic Acid, Ropivacaine, Shoulder, Joint Pain, Postoperative Treatment Outcome, Recovery of Function, Shoulder Pain, Analgesia, Local Anesthetics, Anti-Fibrinolytic Agents, Postoperative Care, Range of Motion, Arti
Conditions
Interventions
Subacromial Tranexamic Acid and Ropivacaine Injection after Arthroscopic Rotator Cuff Repair 0.75%
Ropivacaine Hydrochloride(7.5 mg/ml) 10 ml with Tranexamic acid (50 mg/1 ml) 5ml,Subacromial Ropiva
Active Comparator Drug,Active Comparator Drug
Tranexamic Acid and Ropivacaine group, Ropivacaine group
Sponsors
Faculty of Medicine Vajira Hospital, Navamindradhiraj University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Adults aged 18 to 80 years, 2. Patients diagnosed with a partial-thickness or full-thickness rotator cuff tear,3. confirmed by magnetic resonance imaging , 4. indicated for arthroscopic rotator cuff repair, 5. Patients who are able to provide written informed consent and are willing to comply with the postoperative rehabilitation protocol specified in this study, 6. Rotator cuff tears meeting one of the following criteria 1.Partial-thickness tears from Ellman Grade 1 tears that have failed conservative treatment, or Grade 2 or Grade 3 tears according to the Ellman classification. Full-thickness tears from Small, medium, or large tears classified according to the DeOrio and Cofield classification.
Exclusion criteria
Exclusion criteria: Revision arthroscopic rotator cuff repair, Concomitant proximal humeral, glenoid, or scapular fracture; glenohumeral instability; or irreparable rotator cuff tear, Known hypersensitivity or allergy to amide-type local anesthetics, ropivacaine, or tranexamic acid, History of venous or arterial thromboembolic disease, known bleeding disorders, or current use of anticoagulant therapy, Chronic kidney disease stage 4 or higher, Active infection involving the shoulder or surrounding soft tissues, Pregnancy or breastfeeding, Chronic opioid use, History of substance abuse or illicit drug use.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain 24 hr Visual analog scale | — |
Secondary
| Measure | Time frame |
|---|---|
| Functional score 6, 12,24,52 weeks Constant-Murley score (CMS), Thai version of ASES, | — |
Countries
Thailand
Contacts
Public ContactPetch Natsarun
Vajira hospital
Outcome results
None listed